Loading...

APC anti-mouse CD25 Antibody

Pricing & Availability
Clone
PC61 (See other available formats)
Regulatory Status
RUO
Other Names
IL-2Rα, Ly-43, p55, Tac
Isotype
Rat IgG1, λ
Ave. Rating
Submit a Review
Product Citations
publications
pc61
Con A-stimulated (3 days)splenocytes stained with PC61 APC
  • pc61
    Con A-stimulated (3 days)splenocytes stained with PC61 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
102011 25 µg 44€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
102012 100 µg 125€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD25 is a 55 kD glycoprotein also known as the low affinity IL-2Rα, Ly-43, p55, or Tac. It is expressed on activated T and B cells, thymocyte subsets, pre-B cells, and T regulatory cells. In association with CD122 (IL-2Rβ) and CD132 (common γ chain), CD25 forms the high affinity signaling IL-2 receptor.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
IL-2-dependent cytolytic mouse T-cell clone B6.1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD25 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1,2, in vitro blocking of IL-2 binding to low- and high-affinity receptors1-4, growth inhibition of IL-2-dependent T-cell lines1-4, in vivo depletion of CD25+CD4+ Treg cells5-8,10, and immunohistochemical staining of acetone-fixed frozen sections2. PC61 antibody recognizes a different epitope than 3C7 antibody (Cat. No. 101902). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 102040) with endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered. 

Application References
  1. Lowenthal JW, et al. 1985. Nature 315:669. (IP, Block)
  2. Ceredig R, et al. 1985. Nature 314:98. (IP, IHC, Block)
  3. Lowenthal JW, et al. 1985. J. Immunol. 135:3988. (Block)
  4. Moreau JL, et al. 1987. Eur. J. Immunol. 17:929. (Block)
  5. Takahashi T, et al. 2000. J. Exp. Med. 192:303. (Deplete)
  6. Onizuka S, et al. 1999. Cancer Res. 59:3128. (Deplete)
  7. Lei TC, et al. 2005. Blood 105:4865. (Deplete)
  8. Pasare C, et al. 2004. Immunity 21:733. (Deplete)
  9. León-Ponte M, et al. 2007. Blood 109:3139.
  10. Cao OW, et al. 2007. Blood doi:10.1182/blood-2007-02-073304. (Deplete)
  11. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719.
  12. Liu F, et al. 2011. Arch Toxicol. 85:1383. PubMed
  13. Anguela XM, et al. 2013. Diabetes. 62:551. PubMed
Product Citations
  1. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  2. Tian J, et al. 2021. Autophagy. 17:2586. PubMed
  3. Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed
  4. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
  5. Saxena V, et al. 2022. Cell Rep. 39:110727. PubMed
  6. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  7. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  8. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
  9. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  10. Pinto NA, et al. 2023. Cell Death Differ. :. PubMed
  11. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
  12. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
  13. Sohn HS, et al. 2022. Sci Adv. 8:eabo5284. PubMed
  14. Lee AR, et al. 2023. Cell Commun Signal. 21:44. PubMed
  15. Wang JX, et al. 2023. JCI Insight. 8:. PubMed
  16. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  17. Zhou X, et al. 2023. Sci Rep. 13:6701. PubMed
  18. Shi L, et al. 2019. Theranostics. 9:4115. PubMed
  19. Lyons J, et al. 2018. PLoS Biol. 16:e2002417. PubMed
  20. Prajeeth C,et al. 2017. J Neuroinflammation.. 10.1186/s12974-017-0978-3. PubMed
  21. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
  22. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
  23. Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed
  24. Kolbus D, et al. 2011. Immunobiology. 216:663. PubMed
  25. Noris M, et al. 2009. J Immunol. 183:4249. PubMed
  26. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  27. Waysbort N, et al. 2013. J Immunol. 191:5822. PubMed
  28. Gravano D, et al. 2010. PLoS One. 5:e13528. PubMed
  29. Annu K, et al. 2020. Sci Rep. 10:2359. PubMed
  30. Cheng G, et al. 2021. iScience. 24:102673. PubMed
  31. Shi L, et al. 2021. Immunity. . PubMed
  32. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  33. Kang TH, et al. 2019. Tissue Eng Regen Med. 16:539. PubMed
  34. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  35. Stahlhut M, et al. 2021. Sci Rep. 11:5294. PubMed
  36. Horikoshi M, et al. 2012. PLoS One. 7:e51215. PubMed
  37. Min H, et al. 2015. PLoS One. 10: 0138201. PubMed
  38. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
  39. Zimmermann J, et al. 2017. Eur J Immunol. 10.1002/eji.201747100. PubMed
  40. Rengarajan S, et al. 2020. Cell Rep Med. :1. PubMed
  41. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
  42. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
  43. Park D, et al. 2020. Cancer Res. 80:4172. PubMed
  44. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
  45. Wang SS, et al. 2021. Biomedicines. 9:. PubMed
  46. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
  47. Zhong W, et al. 2022. Nat Commun. 13:4390. PubMed
  48. Chin AL, et al. 2021. Nat Commun. 12:5138. PubMed
  49. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
  50. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  51. Dou G, et al. 2020. Sci Adv. 6:eaba2987. PubMed
  52. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
  53. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
  54. Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed
  55. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
  56. Wigren M, et al. 2011. J Intern Med. 269:546. PubMed
  57. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  58. Pierini A, et al. 2017. JCI Insight. 2. PubMed
  59. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  60. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  61. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  62. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  63. Oomizu S, et al. 2012. Clin Immunol. 143:51. PubMed
  64. Liu X, et al. 2021. Int J Nanomedicine. 16:5675. PubMed
  65. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  66. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  67. Kolev M, et al. 2020. Immunity. 52(3):513-527. PubMed
  68. Aftabizadeh M, et al. 2021. JCI Insight. 6:. PubMed
  69. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
  70. Kang CK, et al. 2021. J Infect Dis. 224:39. PubMed
  71. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
  72. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
  73. Long C, et al. 2016. Toxicol Sci. 152: 85 - 98. PubMed
  74. Baomei Wang et al. 2019. Cell reports. 26(6):1614-1626 . PubMed
  75. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
  76. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
  77. Ahn SH, et al. 2022. Front Endocrinol (Lausanne). 13:846226. PubMed
  78. Kobia FM, et al. 2020. PLoS Biol. 18:e3000850. PubMed
  79. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  80. Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed
  81. Barbet G, et al. 2018. Immunity. 48:584. PubMed
  82. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
  83. Yue X, et al. 2021. EMBO Rep. 22:e52716. PubMed
  84. O'Donoghue GP, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  85. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
  86. Hoover AR, et al. 2022. Clin Transl Med. 12:e937. PubMed
  87. Tanaka S, et al. 2016. Appl Envir Microbiol. 82: 2693 - 2699. PubMed
  88. Chen C, et al. 2020. Front Cell Neurosci. 14:8. PubMed
  89. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
  90. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  91. Alenazy MF, et al. 2022. PLoS One. 17:e0271689. PubMed
  92. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  93. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  94. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  95. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
  96. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
  97. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  98. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  99. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
  100. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
  101. Kashiwakura Y, et al. 2020. Clinical & Experimental Immunology. 202(1):119-135. PubMed
  102. Deptuch T, et al. 2022. Sci Rep. 12:13480. PubMed
  103. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  104. Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed
  105. Angelou CC, et al. 2020. Frontiers in Immunology. 2.586805556. PubMed
  106. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
  107. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  108. Erens C, et al. 2022. Biomedicines. 10:. PubMed
  109. Hester AK, et al. 2022. Cell Rep. 38:110363. PubMed
  110. Park JS, et al. 2022. J Transl Med. 20:85. PubMed
  111. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
RRID
AB_312860 (BioLegend Cat. No. 102011)
AB_312860 (BioLegend Cat. No. 102012)

Antigen Details

Structure
Forms high affinity IL-2R with IL-2Rβ (CD122) and IL-2Rγ (CD132), 55 kD
Distribution

Activated T cells and B cells, thymocyte subset, pre-B cells, T regulatory cells

Function
IL-2 receptor
Ligand/Receptor
IL-2
Cell Type
B cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, Cytokine/Chemokine Receptors
Antigen References
  1. Taniguchi T, et al. 1993. Cell 73:5-8.
  2. Waldmann TA. 1991. J Biol Chem. 266:2681-4.
  3. Read S, et al. 2000. J Exp Med. 192:295-302.
  4. Lowenthal JW, et al. 1985. J Immunol. 135:3988-94.
Gene ID
16184 View all products for this Gene ID
UniProt
View information about CD25 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD25 Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD25 PC61 FC
Biotin anti-mouse CD25 PC61 FC
FITC anti-mouse CD25 PC61 FC
PE anti-mouse CD25 PC61 FC
PE/Cyanine5 anti-mouse CD25 PC61 FC
Purified anti-mouse CD25 PC61 FC,IHC-F,IP,Block,Depletion
PE/Cyanine7 anti-mouse CD25 PC61 FC
Alexa Fluor® 488 anti-mouse CD25 PC61 FC
Alexa Fluor® 647 anti-mouse CD25 PC61 FC
Pacific Blue™ anti-mouse CD25 PC61 FC
Alexa Fluor® 700 anti-mouse CD25 PC61 FC
APC/Cyanine7 anti-mouse CD25 PC61 FC
PerCP/Cyanine5.5 anti-mouse CD25 PC61 FC
PerCP anti-mouse CD25 PC61 FC
Brilliant Violet 421™ anti-mouse CD25 PC61 FC
Brilliant Violet 605™ anti-mouse CD25 PC61 FC
Brilliant Violet 650™ anti-mouse CD25 PC61 FC
Ultra-LEAF™ Purified anti-mouse CD25 PC61 FC,IHC-F,IP,Block,Depletion
Brilliant Violet 510™ anti-mouse CD25 PC61 FC
PE/Dazzle™ 594 anti-mouse CD25 PC61 FC
Brilliant Violet 711™ anti-mouse CD25 PC61 FC
Brilliant Violet 785™ anti-mouse CD25 PC61 FC
Alexa Fluor® 594 anti-mouse CD25 PC61 IHC-F
APC/Fire™ 750 anti-mouse CD25 PC61 FC
TotalSeq™-A0097 anti-mouse CD25 PC61 PG
KIRAVIA Blue 520™ anti-mouse CD25 PC61 FC
TotalSeq™-B0097 anti-mouse CD25 PC61 PG
TotalSeq™-C0097 anti-mouse CD25 PC61 PG
Spark NIR™ 685 anti-mouse CD25 Antibody PC61 FC
PE/Fire™ 640 anti-mouse CD25 PC61 FC
Spark YG™ 581 anti-mouse CD25 PC61 FC
APC/Fire™ 810 anti-mouse CD25 PC61 FC
Brilliant Violet 750™ anti-mouse CD25 PC61 FC
PerCP/Fire™ 780 anti-mouse CD25 PC61 FC
PE/Fire™ 700 anti-mouse CD25 PC61 FC
Spark PLUS UV395™ anti-mouse CD25 PC61 FC
Spark Blue™ 574 anti-mouse CD25 (Flexi-Fluor™) PC61 FC
PerCP/Fire™ 806 anti-mouse CD25 Antibody PC61 FC
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account